MedPath

Clinical Trial News

HonorHealth's Cancer Research Program: A Leader in Clinical Trials and Treatment Innovation

HonorHealth's cancer research program at the HonorHealth Research Institute is at the forefront of cancer treatment innovation, offering patients access to clinical trials from phase I to IV. The program emphasizes early drug development, providing patients with new medications and treatment approaches before they are widely available. With a comprehensive support system, including navigators and concierge services, HonorHealth is dedicated to advancing medical care and improving patient outcomes.

Ceftriaxone Shows Promise in Alleviating Fatigue in Post-Lyme Disease Syndrome

  • A randomized, double-blind, placebo-controlled trial assessed the efficacy of ceftriaxone in treating post-Lyme disease syndrome (PLS) patients with persistent fatigue.
  • Ceftriaxone therapy demonstrated a significant improvement in fatigue compared to placebo in PLS patients, as measured by a fatigue questionnaire.
  • The study found no beneficial effect of ceftriaxone on cognitive function or experimental measures of persistent infection in PLS patients.
  • Due to adverse events and the improvement of only fatigue, the study does not support routine antibiotic therapy with ceftriaxone for PLS patients.

Home-Based Exercise Program Significantly Reduces Knee Pain, Study Finds

A two-year study involving 786 participants with knee pain found that a simple home-based exercise program significantly reduces knee pain and improves physical function. The study highlights the importance of exercise adherence for pain reduction and suggests that social support alone does not improve health outcomes.

Intensive Chemo Shows Promise in Relapsed Ovarian Cancer

  • A new intensive chemotherapy regimen demonstrates high effectiveness in treating women with relapsed ovarian cancer after initial chemotherapy failure.
  • The treatment, combining cisplatin and etoposide, achieved an 80% tumor shrinkage rate, with 43% of patients showing complete remission.
  • The intensive regimen, involving weekly cisplatin administration, proved more effective than standard therapies, offering new hope for patients with limited options.
  • Researchers noted the treatment was well-tolerated, with manageable side effects, and the drugs are readily available for immediate patient benefit.

ASCO 2024: Lenvatinib plus Pembrolizumab Shows Superiority Over Sunitinib in Advanced Renal Cell Carcinoma

At the 2024 ASCO Annual Meeting, Dr. Viktor Grünwald presented findings from the CLEAR trial, highlighting the efficacy of lenvatinib plus pembrolizumab over sunitinib in treating advanced clear cell renal cell carcinoma. The combination therapy demonstrated significant improvements in overall survival, prolonged time to tumor progression across various organs, and a lower median tumor burden at disease progression.

Regional Chemotherapy for Liver Metastases of Colorectal Cancer Shows Varied Perfusion Patterns

A study involving 82 patients with liver metastases from colorectal cancer treated with continuous chemotherapy via hepatic artery infusion pumps revealed varied liver perfusion patterns. While 70% of patients showed homogeneous liver perfusion, 24% had distinct inhomogeneities, and 6% exhibited selective perfusion of one hepatic lobe, impacting the response to therapy.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy